Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a clinical-stage biopharmaceutical company developing cell-based platforms to potentiate oncolytic virotherapies for the treatment of cancer. The company went public in September 2023 through its business combination with FLAG Ship Acquisition Corp II, a blank-check vehicle that completed its IPO in 2021 with FLAG Ship Investment Partners serving as sponsor. An S-1/A registration statement amendment was filed with the Securities and Exchange Commission on April 15, 2024, reflecting the company's ongoing post-merger reporting obligations. Calidi operates in the oncology segment of the broader biopharmaceutical sector. Sign up on SpacDesk for full filing history, deal analytics, and SPAC transaction data on CLDI.